The Impedimed share price was higher today after the company announced that AstraZeneca would use its Sozo device in a trial.
The post Here’s why the Impedimed (ASX:IPD) share price shot up 13% today appeared first on Motley Fool Australia. –
The Impedimed Limited (ASX: IPD) share price rocketed by 13.41% today to close the day’s trade at 9.3 cents per share. This came after the company announced that its Sozo medical device has been selected by AstraZeneca for use in a phase 2 drug trial.
What did Impedimed announce?
Impedimed is a medical device company that produces a family of FDA-approved devices. It has been listed on the ASX since 2007.
According to Impedimed, pharmaceutical giant AstraZeneca has selected its Sozo device for a phase 2 trial in order to measure fluid volume in patients with chronic kidney disease. The AstraZeneca study will use the Impedimed device to evaluate the efficacy, safety and tolerability of a combination of 2 AstraZeneca drugs.
The trial will begin in January 2021 and run for approximately 18 months. According to Impedimed, the study will generate $2 million in revenue. The total expected revenue from this trial and a previously announced AstraZeneca trial, in which it is also using Sozo, is $4.5 million.
An additional 200 Sozo devices will be leased across 24 countries for the trial, bringing the total Sozo devices leased for AstraZeneca studies to 375.
Impedimed managing director and CEO Richard Carreon commented: “There are millions of people today living with chronic kidney disease, and we look forward to learning more about the impact this trial will have on improving patient care.”
How has Impedimed performed recently?
In the first quarter of FY2021, Impedimed had revenue of $1.5 million, an increase of 11% on the prior corresponding period. Impedimed had $15.4 million cash on hand at 30 September 2020.
The Impedimed share price is up more than 187% since its 52-week low of 3.2 cents, however, it is down 38% since the beginning of the year. The Impedimed share price is down 34% since this time last year.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- The A2 Milk (ASX:A2M) share price is up 4% today. Here’s why.
- Why the Resapp (ASX:RAP) share price stormed 5% higher today
- The RPMGlobal (ASX:RUL) share price is up 9% in a week. Here’s why.
- ASX stock of the day: Elixinol Global (ASX:EXL) shares blaze new highs
- Leading brokers name 3 ASX shares to buy today
Motley Fool contributor Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.